ly 300502 has been researched along with alfuzosin in 1 studies
*alfuzosin: structure given in first source [MeSH]
*alfuzosin: structure given in first source [MeSH]
| Studies (ly 300502) | Trials (ly 300502) | Recent Studies (post-2010) (ly 300502) | Studies (alfuzosin) | Trials (alfuzosin) | Recent Studies (post-2010) (alfuzosin) |
|---|---|---|---|---|---|
| 6 | 0 | 0 | 427 | 127 | 120 |
| Protein | Taxonomy | ly 300502 (IC50) | alfuzosin (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Homo sapiens (human) | 0.018 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.023 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.023 | |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | 0.023 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballard, S; Blagg, J; Fox, D; Kenny, B | 1 |
1 review(s) available for ly 300502 and alfuzosin
| Article | Year |
|---|---|
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlled Clinical Trials as Topic; Endothelins; Enzyme Inhibitors; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Structure-Activity Relationship | 1997 |